



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/693,164	10/24/2003	Carson R. Loomis	067437-5019US	1674
67374	7590	04/12/2007	EXAMINER	
MORGAN, LEWIS & BOCKIUS, LLP			LANDSMAN, ROBERT S	
ONE MARKET SPEAR STREET TOWER			ART UNIT	PAPER NUMBER
SAN FRANCISCO, CA 94105			1647	
SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE		DELIVERY MODE	
2 MONTHS	04/12/2007		PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	10/693,164	LOOMIS ET AL.	
	Examiner	Art Unit	
	Robert Landsman, Ph.D.	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 2 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 03 April 2007.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,3,4,8-27,55,57,58,62-81,109 and 110 is/are pending in the application.
- 4a) Of the above claim(s) 15 and 69 is/are withdrawn from consideration.
- 5) Claim(s) 1,3,4,8-14,16-27,55,57,58,62-68,70-81,109 and 110 is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

1. Formal Matters

- A. The Amendment filed 4/3/07 has been entered into the record.
- B. Claims 1, 3, 4, 8-27, 55, 57, 58, 62-81, 109 and 110 are pending. Claims 15 and 69 have been withdrawn as drawn to a non-elected invention. Therefore, claims 1, 3, 4, 8-14, 16-27, 55, 57, 58, 62-68, 70-81, 109 and 110 are the subject of this Office Action.

2. Specification

- A. When a sequence is presented in a drawing, regardless of the format or the manner of presentation of that sequence in the drawing, the sequence must still be included in the Sequence Listing and a sequence identifier ("SEQ ID NO:X") must be used either in the drawing or in the Brief Description of the Drawings. See MPEP ' 2422.02. In the instant application, a sequence identifier must be used for the sequences appearing in Figure 2.
- B. The US Application 09/933,844 in paragraph [0010] should be updated to the issued patent.

3. Claim Objections

- A. Claims 15 and 69, as well as any other non-elected claims, should be cancelled.
- B. Claim 55 is objected to since the preamble recites "TRM signaling" and "TMR internalization" instead of "GPCR."

Art Unit: 1647

4. Art of Interest

A. U.S. Patent No. 6,726,588 has been cited to demonstrate that various receptor screening methods, including those using a time course and other points of measure, were well known in the art at the time of the present invention. No art rejection is being made, however, in view of the fact that, although measuring time courses and dose-response relationships for receptor functions such as internalization and second messenger activities were well known at the time of the invention, the Examiner could not make a *prima facie* case that measuring the time course or dose-response relationships for internalization in comparison to that of signal transduction (second messenger activity) would have been obvious. As stated, a reasonable search of the art demonstrates that internalization, itself, is widely studied, as is the dose-response relationships of numerous GPCR second messenger activities. However, there is little to no overlap on the discussion of utilizing these assays/measurements in conjunction to study each other.

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (571) 272-0888. The examiner can normally be reached on M-Th 10 AM – 7 PM (eastern).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Robert Landsman, Ph.D.
Primary Examiner
Art Unit 1647